רווח למניה בשנים עשר החודשים האחרונים: NAYA Biosciences Inc (NAYA)

Oncology therapy developer NAYA Biosciences (NAYA) faces a lack of stable revenue and a dependence on external capital; therefore, analyzing the chart on GURU.Markets, we find that the current trailing annual EPS value of -30.56 is the current figure. NAYA Biosciences (NAYA) is scaling its clinical portfolio and fertility IT services, leveraging its proprietary antibody creation platform to develop targeted drugs.

Investors seek a balance between asset valuation and the quality of fundamental indicators. This metric measures the total annual profit distributed per share, excluding the impact of the total issuance volume. For NAYA Biosciences, this calculation reflects the capitalization efficiency of its antibody patent platform. The high intellectual premium of future products must be validated by growth in the rolling annual earnings per share.